Christopher Richard Anzalone
CIK: 0001423029
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ARROWHEAD PHARMACEUTICALS, INC.
Discretionary Trading P&L
Holdings
Transaction History (46 total)
- Jan 2, 2026ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct5.8K shares at avg. $66.39$383K - Jan 2, 2026ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct7.4K shares at avg. $65.88$489K - Dec 29, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct35.2K shares at avg. $69.33$2.4M - Dec 29, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct16.5K shares at avg. $68.69$1.1M - Dec 29, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Exercise(M)Direct35.2K shares at avg. $6.15$216K - Dec 29, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Exercise(M)Direct16.5K shares at avg. $6.15$102K - Dec 22, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct2.6K shares at avg. $68.85$177K - Dec 22, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct10K shares at avg. $68.33$684K - Dec 19, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct1.3K shares at avg. $68.48$90K - Dec 19, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct8.1K shares at avg. $68.01$554K - Dec 19, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct4K shares at avg. $66.67$265K - Dec 17, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct2K shares at avg. $66.30$131K - Dec 17, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct982 shares at avg. $65.53$64K - Dec 17, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct35.8K shares at avg. $64.51$2.3M - Dec 17, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct46.3K shares at avg. $63.55$2.9M - Dec 16, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct1.3K shares at avg. $65.77$86K - Dec 16, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct8.4K shares at avg. $60.51$509K - Dec 16, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct11K shares at avg. $61.25$671K - Dec 16, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct14.1K shares at avg. $62.12$876K - Dec 16, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct8.5K shares at avg. $62.94$533K - Dec 16, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct6.7K shares at avg. $64.29$428K - Dec 16, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct1K shares at avg. $64.96$65K - Dec 16, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct166 shares at avg. $66.77$11K - Dec 16, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct3.2K shares at avg. $67.87$219K - Dec 15, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct8.1K shares at avg. $69.96$570K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 2, 2026 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 5,771 | $66.39 | $383,137 | Direct |
| Jan 2, 2026 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 7,416 | $65.88 | $488,566 | Direct |
| Dec 29, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 35,181 | $69.33 | $2,439,099 | Direct |
| Dec 29, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 16,545 | $68.69 | $1,136,476 | Direct |
| Dec 29, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Exercise(M) | 35,181 | $6.15 | $216,363 | Direct |
| Dec 29, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Exercise(M) | 16,545 | $6.15 | $101,752 | Direct |
| Dec 22, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 2,574 | $68.85 | $177,220 | Direct |
| Dec 22, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 10,012 | $68.33 | $684,120 | Direct |
| Dec 19, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 1,319 | $68.48 | $90,325 | Direct |
| Dec 19, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 8,147 | $68.01 | $554,077 | Direct |
| Dec 19, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 3,979 | $66.67 | $265,280 | Direct |
| Dec 17, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 1,981 | $66.30 | $131,340 | Direct |
| Dec 17, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 982 | $65.53 | $64,350 | Direct |
| Dec 17, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 35,750 | $64.51 | $2,306,233 | Direct |
| Dec 17, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 46,287 | $63.55 | $2,941,539 | Direct |
| Dec 16, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 1,300 | $65.77 | $85,501 | Direct |
| Dec 16, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 8,416 | $60.51 | $509,252 | Direct |
| Dec 16, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 10,963 | $61.25 | $671,484 | Direct |
| Dec 16, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 14,095 | $62.12 | $875,581 | Direct |
| Dec 16, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 8,476 | $62.94 | $533,479 | Direct |
| Dec 16, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 6,661 | $64.29 | $428,236 | Direct |
| Dec 16, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 1,000 | $64.96 | $64,960 | Direct |
| Dec 16, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 166 | $66.77 | $11,084 | Direct |
| Dec 16, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 3,221 | $67.87 | $218,609 | Direct |
| Dec 15, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 8,147 | $69.96 | $569,964 | Direct |
1-25 of 46 transactions
About Anzalone Christopher Richard
Anzalone Christopher Richard (SEC CIK 0001423029) files insider reports with the SEC as Chief Executive Officer of ARROWHEAD PHARMACEUTICALS, INC. (ARWR).
Signal8 holds 12 ownership filings by Anzalone Christopher Richard, all Form 4s, filed between Dec 20, 2024 and Jan 5, 2026. Those filings report 46 transactions, from Dec 18, 2024 to Jan 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Anzalone Christopher Richard's filings is in PASADENA, CA.
Recent filings by Anzalone Christopher Richard
- Jan 2, 2026: Open-market sales of ARWR shares (2 lines, Form 4, code S).
- Dec 29, 2025: Open-market sales of ARWR shares (2 lines, Form 4, code S).
- Dec 29, 2025: Option exercises of ARWR shares (2 lines, Form 4, code M).
- Dec 22, 2025: Open-market sales of ARWR shares (2 lines, Form 4, code S).
- Dec 19, 2025: Open-market sales of ARWR shares (3 lines, Form 4, code S).
Other insiders filing for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
- OLUKOTUN ADEOYE Y, Director
- PERRY MICHAEL S, Director
- Cohen Matthew Gregory, Director
- Lu Hongbo, Director
- Apel Daniel Joseph, Chief Financial Officer
- Hamilton James C, Chief Medical Officer